LLY vs. UBER: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at LLY and UBER, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | LLY | UBER |
|---|---|---|
| Company Name | Eli Lilly and Company | Uber Technologies, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Industrials |
| GICS Industry | Pharmaceuticals | Ground Transportation |
| Market Capitalization | 592.10 billion USD | 189.42 billion USD |
| Exchange | NYSE | NYSE |
| Listing Date | June 1, 1972 | May 10, 2019 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of LLY and UBER by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | LLY | UBER |
|---|---|---|
| 5-Day Price Return | 3.06% | -1.99% |
| 13-Week Price Return | -12.58% | 3.10% |
| 26-Week Price Return | -24.11% | 29.78% |
| 52-Week Price Return | -25.32% | 31.14% |
| Month-to-Date Return | -10.75% | 3.51% |
| Year-to-Date Return | -14.44% | 50.58% |
| 10-Day Avg. Volume | 8.71M | 21.46M |
| 3-Month Avg. Volume | 4.45M | 21.23M |
| 3-Month Volatility | 41.63% | 32.88% |
| Beta | 0.45 | 1.49 |
Profitability
Return on Equity (TTM)
LLY
88.36%
Pharmaceuticals Industry
- Max
- 38.59%
- Q3
- 19.84%
- Median
- 11.90%
- Q1
- 5.63%
- Min
- -9.96%
LLY’s Return on Equity of 88.36% is exceptionally high, placing it well beyond the typical range for the Pharmaceuticals industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
UBER
62.42%
Ground Transportation Industry
- Max
- 22.11%
- Q3
- 13.84%
- Median
- 9.66%
- Q1
- 7.55%
- Min
- 0.36%
UBER’s Return on Equity of 62.42% is exceptionally high, placing it well beyond the typical range for the Ground Transportation industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.
Net Profit Margin (TTM)
LLY
25.91%
Pharmaceuticals Industry
- Max
- 34.51%
- Q3
- 17.73%
- Median
- 12.12%
- Q1
- 5.99%
- Min
- -7.73%
A Net Profit Margin of 25.91% places LLY in the upper quartile for the Pharmaceuticals industry, signifying strong profitability and more effective cost management than most of its peers.
UBER
26.68%
Ground Transportation Industry
- Max
- 32.20%
- Q3
- 18.59%
- Median
- 7.11%
- Q1
- 4.13%
- Min
- -10.38%
A Net Profit Margin of 26.68% places UBER in the upper quartile for the Ground Transportation industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
LLY
32.37%
Pharmaceuticals Industry
- Max
- 41.53%
- Q3
- 23.00%
- Median
- 16.24%
- Q1
- 9.24%
- Min
- -6.94%
An Operating Profit Margin of 32.37% places LLY in the upper quartile for the Pharmaceuticals industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
UBER
9.03%
Ground Transportation Industry
- Max
- 41.31%
- Q3
- 23.16%
- Median
- 11.33%
- Q1
- 6.82%
- Min
- -12.08%
UBER’s Operating Profit Margin of 9.03% is around the midpoint for the Ground Transportation industry, indicating that its efficiency in managing core business operations is typical for the sector.
Profitability at a Glance
| Symbol | LLY | UBER |
|---|---|---|
| Return on Equity (TTM) | 88.36% | 62.42% |
| Return on Assets (TTM) | 16.02% | 24.38% |
| Net Profit Margin (TTM) | 25.91% | 26.68% |
| Operating Profit Margin (TTM) | 32.37% | 9.03% |
| Gross Profit Margin (TTM) | 82.64% | 33.93% |
Financial Strength
Current Ratio (MRQ)
LLY
1.28
Pharmaceuticals Industry
- Max
- 4.49
- Q3
- 2.77
- Median
- 1.74
- Q1
- 1.26
- Min
- 0.11
LLY’s Current Ratio of 1.28 aligns with the median group of the Pharmaceuticals industry, indicating that its short-term liquidity is in line with its sector peers.
UBER
1.11
Ground Transportation Industry
- Max
- 2.03
- Q3
- 1.26
- Median
- 0.89
- Q1
- 0.73
- Min
- 0.38
UBER’s Current Ratio of 1.11 aligns with the median group of the Ground Transportation industry, indicating that its short-term liquidity is in line with its sector peers.
Debt-to-Equity Ratio (MRQ)
LLY
2.18
Pharmaceuticals Industry
- Max
- 2.44
- Q3
- 1.07
- Median
- 0.42
- Q1
- 0.11
- Min
- 0.00
LLY’s leverage is in the upper quartile of the Pharmaceuticals industry, with a Debt-to-Equity Ratio of 2.18. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
UBER
0.42
Ground Transportation Industry
- Max
- 2.51
- Q3
- 1.51
- Median
- 1.06
- Q1
- 0.47
- Min
- 0.00
Falling into the lower quartile for the Ground Transportation industry, UBER’s Debt-to-Equity Ratio of 0.42 points to a conservative financing strategy. This results in lower financial risk but potentially limits strategic investments compared to more leveraged competitors.
Interest Coverage Ratio (TTM)
LLY
20.36
Pharmaceuticals Industry
- Max
- 103.95
- Q3
- 44.18
- Median
- 9.83
- Q1
- 2.82
- Min
- -42.71
LLY’s Interest Coverage Ratio of 20.36 is positioned comfortably within the norm for the Pharmaceuticals industry, indicating a standard and healthy capacity to cover its interest payments.
UBER
-0.24
Ground Transportation Industry
- Max
- 51.07
- Q3
- 22.54
- Median
- 7.94
- Q1
- 2.72
- Min
- -24.57
UBER has a negative Interest Coverage Ratio of -0.24. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.
Financial Strength at a Glance
| Symbol | LLY | UBER |
|---|---|---|
| Current Ratio (MRQ) | 1.28 | 1.11 |
| Quick Ratio (MRQ) | 0.53 | 0.97 |
| Debt-to-Equity Ratio (MRQ) | 2.18 | 0.42 |
| Interest Coverage Ratio (TTM) | 20.36 | -0.24 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
LLY
0.82%
Pharmaceuticals Industry
- Max
- 6.98%
- Q3
- 3.32%
- Median
- 2.13%
- Q1
- 0.14%
- Min
- 0.00%
LLY’s Dividend Yield of 0.82% is consistent with its peers in the Pharmaceuticals industry, providing a dividend return that is standard for its sector.
UBER
0.00%
Ground Transportation Industry
- Max
- 5.44%
- Q3
- 2.49%
- Median
- 1.53%
- Q1
- 0.39%
- Min
- 0.00%
UBER currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.
Dividend Payout Ratio (TTM)
LLY
36.46%
Pharmaceuticals Industry
- Max
- 165.20%
- Q3
- 90.59%
- Median
- 49.13%
- Q1
- 28.91%
- Min
- 0.00%
LLY’s Dividend Payout Ratio of 36.46% is within the typical range for the Pharmaceuticals industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
UBER
0.00%
Ground Transportation Industry
- Max
- 137.07%
- Q3
- 74.71%
- Median
- 41.16%
- Q1
- 15.12%
- Min
- 0.00%
UBER has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.
Dividend at a Glance
| Symbol | LLY | UBER |
|---|---|---|
| Dividend Yield (TTM) | 0.82% | 0.00% |
| Dividend Payout Ratio (TTM) | 36.46% | 0.00% |
Valuation
Price-to-Earnings Ratio (TTM)
LLY
44.55
Pharmaceuticals Industry
- Max
- 42.51
- Q3
- 26.88
- Median
- 19.11
- Q1
- 15.12
- Min
- 0.00
At 44.55, LLY’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Pharmaceuticals industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.
UBER
14.99
Ground Transportation Industry
- Max
- 42.59
- Q3
- 24.86
- Median
- 16.38
- Q1
- 12.79
- Min
- 4.37
UBER’s P/E Ratio of 14.99 is within the middle range for the Ground Transportation industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
LLY
11.54
Pharmaceuticals Industry
- Max
- 7.55
- Q3
- 4.54
- Median
- 2.11
- Q1
- 1.52
- Min
- 0.00
With a P/S Ratio of 11.54, LLY trades at a valuation that eclipses even the highest in the Pharmaceuticals industry. This implies the market has priced in exceptionally optimistic scenarios for future revenue growth, posing considerable valuation risk.
UBER
4.00
Ground Transportation Industry
- Max
- 4.02
- Q3
- 2.20
- Median
- 1.23
- Q1
- 0.87
- Min
- 0.22
UBER’s P/S Ratio of 4.00 is in the upper echelon for the Ground Transportation industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
Price-to-Book Ratio (MRQ)
LLY
40.43
Pharmaceuticals Industry
- Max
- 9.78
- Q3
- 4.96
- Median
- 2.23
- Q1
- 1.46
- Min
- 0.60
At 40.43, LLY’s P/B Ratio is at an extreme premium to the Pharmaceuticals industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
UBER
8.63
Ground Transportation Industry
- Max
- 4.95
- Q3
- 2.78
- Median
- 1.38
- Q1
- 1.17
- Min
- 0.64
At 8.63, UBER’s P/B Ratio is at an extreme premium to the Ground Transportation industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.
Valuation at a Glance
| Symbol | LLY | UBER |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 44.55 | 14.99 |
| Price-to-Sales Ratio (TTM) | 11.54 | 4.00 |
| Price-to-Book Ratio (MRQ) | 40.43 | 8.63 |
| Price-to-Free Cash Flow Ratio (TTM) | 305.94 | 22.17 |